Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75250 | 0.85 | CYP4F2 (0.48) | NPC1RAB9AL3MBTL1CYP19A1PKM | |
| SCHEMBL75201 | 0.84 | NPC1 (0.43) | NPC1RAB9AL3MBTL1CYP19A1PKM | |
| SCHEMBL75792 | 0.82 | CYP19A1 (0.44) | NPC1RAB9ACYP19A1LMNA | |
| SCHEMBL5070843 | 0.80 | RAB9A (0.56) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL74511 | 0.79 | HRH3 (0.51) | KCNH2 | |
| SCHEMBL75868 | 0.79 | NPC1 (0.49) | NPC1RAB9AL3MBTL1CYP19A1PKM | |
| SCHEMBL85712 | 0.78 | NPC1 (0.48) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL73957 | 0.75 | NPC1 (0.48) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL92863 | 0.73 | CYP19A1 (0.43) | L3MBTL1CYP19A1PKMSMN1; SMN2MEN1 | |
| SCHEMBL85713 | 0.73 | NPC1 (0.48) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945206-B1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | disclosed |
| US-7855224-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7528262-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | BENNANI YOUSSEF L | 2009-02-05 | — | — | US | disclosed |
| US-20070161676-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HCRTR1, HCRTR2 | NPC1 1329/4885RAB9A 2187/4885L3MBTL1 2261/4885 |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | HRH3, HCRTR1, HCRTR2 | NPC1 1329/4885RAB9A 2187/4885L3MBTL1 2261/4885 |
| US-20070161676-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HCRTR1, HCRTR2 | NPC1 1329/4885RAB9A 2187/4885L3MBTL1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.